. Author manuscript; available in PMC: 2021 Jul 1.

Published in final edited form as: Muscle Nerve. 2020 Feb 24;61(5):587–594. doi: 10.1002/mus.26833

TABLE 1.

Demographic and disease characteristics of the participants

Parameter		Mean (SD) or n (%)
Age, mean (SD)		55.4 (10.5)
BMI, mean (SD)		29.8 (6.9)
Stage of breast cancer, n (%)	Stage I	8 (40%)
Stage of breast cancer, n (%)	Stage II	5 (25%)
	Stage III	2 (10%)
	Stage IV	5 (25%)
Prior radiation therapy, n (%)		10 (50%)
Prior surgery for breast cancer, n (%)		19 (95%)
Prior hormone therapy for breast cancer, n (%)		8 (40%)
Prior lines of systemic cancer therapy, median (IQR)		1(1–3)
Most recent taxane, n (%)	Paclitaxel	10 (50%)
Most recent taxane, n (%)	Docetaxel	8 (40%)
	Nab-paclitaxel	2 (10%)
Cumulative taxane dose, mg/m², mean (SD)		817.3 (414.9)
Months since last taxane dose, median (IQR)		3.8 (1.0–6.1)
Relevant comorbidities, n (%)	Diabetes, no end-organ damage	4 (20%)
Relevant comorbidities, n (%)	Hypothyroidism	3 (15%)
	Depression	3 (15%)
	Alcoholism	1(5%)
	Cerebovascular disease	1 (5%)
	Vitamin B12 deficiency	1 (5%)

IQR, interquartile range; Nab, nanoparticle albumin–bound.